The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,542,284 in first-year total cost, median $286,081.
Most frequent study sections
- Special Emphasis Panel[ZRG1 BST-R (10)]2
- Special Emphasis Panel[ZRG1 BST-F (10)]1
Most frequent institutions
- GRADIENT MEDICAL, INC.1
- SIVEC BIOTECHNOLOGIES, LLC1
- STRM.BIO, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2022 | Bone marrow-targeted extracellular vesicles as a novel non-viral gene editor delivery platform1R44TR004238-01 | THON, JONATHAN N | STRM.BIO, INC., MA | $1,004,289 | ZRG1 |
| 2021 | A large-capacity bacterial platform for the production and targeted delivery of gene editing systems1R43TR003962-01A1 | LINKE, LYNDSEY | SIVEC BIOTECHNOLOGIES, LLC, CO | $286,081 | ZRG1 |
| 2021 | Feasibility of INSPIRE Technology to Enhance CRISPR Mediated Genome Editors In Vivo1R43GM143999-01 | FONG, JORDAN | GRADIENT MEDICAL, INC., NC | $251,914 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.